Medical Condition News

RSS

Meniscal, cruciate ligament lesions increase risk of knee osteoarthritis

Arthroscopic surgical repair of torn anterior cruciate ligaments (ACL) or meniscal cartilage injuries in the knee does not decrease the chances of developing osteoarthritis, according to a new study published in the online edition and August print issue of the journal Radiology.

29 Jun 2010

Researchers suggest factors that predict pre-Alzheimer's condition

Mild cognitive impairment is often seen as a transition stage between the cognitive decline of normal aging and the more serious problems of Alzheimer's disease. But what leads to mild cognitive impairment?

29 Jun 2010

FDA approves Teva's generic Effexor XR antidepressant

Teva Pharmaceutical Industries Ltd. announced today U.S. Food and Drug Administration (FDA) approval of Venlafaxine HCl ER Capsules, the Company's generic version of Wyeth's antidepressant Effexor XR®. Shipment is expected to commence on July 1, 2010, as per the terms of the 2006 agreement with Wyeth.

29 Jun 2010

AFREZZA provides long-term glucose control in Type 2 diabetics: Study

AFREZZA (insulin human [rDNA origin]) Inhalation Powder, a well-tolerated, investigational ultra rapid acting mealtime insulin, as part of a diabetes treatment regimen, provides long-term glucose control comparable to usual insulin therapy but with a significantly reduced incidence of hypoglycemia and less weight gain in patients with Type 2 diabetes, according to a two-year study presented today at the American Diabetes Association's 70th Scientific Sessions.

29 Jun 2010

Researchers use neonatal piglet model to study infant brain development

Events occurring during the development of an infant's brain can leave behind fingerprints. And researchers at the University of Illinois are interested in learning how these fingerprints can predict future behavioral problems such as cognitive deficits, anxiety disorders, depression, and even autism.

29 Jun 2010

Avila's AVL-292 demonstrates disease-modifying effects in prophylactic, therapeutic models of rheumatoid arthritis

Avila Therapeutics™, Inc., a biotechnology company developing targeted covalent drugs that treat diseases through protein silencing, today announced results of preclinical studies demonstrating that its clinical candidate, AVL-292, potently inhibits B cell receptor signaling, and demonstrates efficacy in a rodent model of rheumatoid arthritis. These new data were presented Saturday, June 26, 2010 at the Federation of Clinical Immunology Societies (FOCIS) 2010 annual meeting in Boston, MA.

29 Jun 2010

Young breast cancer patients more likely to discontinue hormone therapy

A new study of nearly 8,800 women with early-stage breast cancer found that fewer than half - approximately 49 percent - completed their full regimen of hormone therapy according to the prescribed schedule.

29 Jun 2010

Marcadia, Eli Lilly sign development, license agreement for short-acting glucagon program

Marcadia Biotech, Inc. and Eli Lilly and Company today announced that the companies have signed a development and exclusive license agreement for Marcadia's short-acting glucagon program, covering glucagon analogs that may provide greater convenience and ease-of-use than the current recombinant glucagon for the treatment of severe hypoglycemia. The program includes MAR531, a glucagon analog that is in preclinical development at Marcadia, as well as related backup compounds.

29 Jun 2010

Literature review discusses herniated disks and treatment options for low back pain

A literature review, led by Dr. Joseph Lee, published in the June 2010 issue of the Journal of the American Academy of Orthopaedic Surgeons (JAAOS) suggests that a herniated disk is one of the most frequent causes of low back and leg pain in adults, but surgery is not for everyone. Between 60 and 80 percent of people will experience low back pain at some point in their lives

29 Jun 2010

MGH, Iacocca Foundation complete Phase I BCG clinical trial in type 1 diabetes

Massachusetts General Hospital (MGH) and the Iacocca Foundation announce today the completion of the Phase I BCG clinical trial in type 1 diabetes, as well as the submission of all safety reports to the U.S. Food and Drug Administration (FDA) and the MGH data safety monitoring boards. Plans for the Phase II clinical study, which will continue the investigation of bacillus Calmette-Guerin (BCG) vaccination as a treatment for people with existing type 1 diabetes, are actively underway.

29 Jun 2010

Rosiglitazone associated with increased risk of serious cardiovascular events compared with pioglitazone

A new study published online today by JAMA shows that among patients age 65 years and older, rosiglitazone (a medication for treating Type 2 diabetes) is associated with an increased risk of stroke, heart failure, and all-cause mortality (death) when compared with pioglitazone (another medication for diabetes). The study was published online today in advance of an upcoming Food and Drug Administration meeting that will review the safety of rosiglitazone. The paper will appear in the July 28 print issue of JAMA.

29 Jun 2010

Failed ACL surgeries are more common than previously thought

Nick Van Erp, active in soccer since elementary school and lacrosse since junior high, tore the anterior cruciate ligament in his knee during a spring lacrosse game his freshman year of high school. His injury, caused by stepping into a pothole and hyper-extending his knee, required surgical repair, ending his season prematurely and the remainder of his high school sports career.

29 Jun 2010

EpiCept requests FDA priority review of Ceplene NDA for AML

EpiCept Corporation announced today that it has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for Ceplene® (histamine dihydrochloride). EpiCept is seeking approval for Ceplene, administered concomitantly with low-dose interleukin-2 (IL-2), for the remission maintenance and prevention of relapse in patients with Acute Myeloid Leukemia (AML) in first complete remission.

29 Jun 2010

Endometriosis can affect women's work productivity

The first worldwide study of the societal impact of endometriosis has found a significant loss of work productivity among those women who suffer from the condition, a researcher told the 26th annual meeting of the European Society of Human Reproduction and Embryology today (Monday).

29 Jun 2010

BioAlliance Pharma presents abstracts on Loramyc, clonidine Lauriad at MASCC/ISOO 2010 symposium

BioAlliance Pharma SA, a company dedicated to the supportive care and treatment of cancer patients, has presented 2 abstracts on Loramyc® and clonidine Lauriad® at the MASCC/ISOO 2010 International Symposium (Vancouver, June 24-26, 2010). These two products belong to the supportive care pipeline of BioAlliance Pharma.

29 Jun 2010

Psychiatry and Pediatrics seeks volunteer families to participate in vitamin D study

Associate Professor Emeritus of Psychiatry and Pediatrics (OHSU, Portland, Oregon) is seeking roughly 50-100 volunteer families to participate in a vitamin D study. The goal of the study is to find out whether giving Vitamin D to the pregnant mother, who already has had at least one previous child with autism, can prevent the recurrence of autism in the newborn sibling.

29 Jun 2010

Forest Laboratories, Gedeon Richter report positive results from radiprodil Phase II study for DPNP pain

Forest Laboratories, Inc. and Gedeon Richter Plc. today announced top-line results from a Phase II placebo and positive comparator-controlled, parallel-arm, double-blind, dose-response clinical trial of the novel, investigational NR2B-selective NMDA (N-methyl D-aspartate) receptor antagonist, radiprodil (RGH-896), for the treatment of neuropathic pain associated with diabetic peripheral neuropathy (DPNP).

29 Jun 2010

FDA's acceptance for filing of DM-1796 NDA triggers $10M milestone payment to Depomed

Depomed, Inc. today announced that it has received a $10 million milestone payment from Abbott Products, Inc., its licensee of DM-1796, for the U.S. Food and Drug Administration's acceptance for filing of the New Drug Application (NDA) for DM-1796 for the management of postherpetic neuralgia (PHN), or pain after shingles.

29 Jun 2010

UB study: Vietnam veterans exposed to Agent Orange are more likely to develop Graves' disease

Vietnam War-era veterans exposed to Agent Orange appear to have significantly more Graves' disease, a thyroid disorder, than veterans with no exposure, a new study by endocrinologists at the University at Buffalo has shown.

29 Jun 2010

New brain-to-computer chip technology revolutionizes neurological therapy

By stimulating certain areas of the brain, scientists can alleviate the effects of disorders such as depression or Parkinson's disease. That's the good news. But because controlling that stimulation currently lacks precision, over-stimulation is a serious concern - losing some of its therapeutic benefits for the patient over time.

29 Jun 2010

Medical Condition News

Meniscal, cruciate ligament lesions increase risk of knee osteoarthritis

Researchers suggest factors that predict pre-Alzheimer's condition

FDA approves Teva's generic Effexor XR antidepressant

AFREZZA provides long-term glucose control in Type 2 diabetics: Study

Researchers use neonatal piglet model to study infant brain development

Avila's AVL-292 demonstrates disease-modifying effects in prophylactic, therapeutic models of rheumatoid arthritis

Young breast cancer patients more likely to discontinue hormone therapy

Marcadia, Eli Lilly sign development, license agreement for short-acting glucagon program

Literature review discusses herniated disks and treatment options for low back pain

MGH, Iacocca Foundation complete Phase I BCG clinical trial in type 1 diabetes

Rosiglitazone associated with increased risk of serious cardiovascular events compared with pioglitazone

Failed ACL surgeries are more common than previously thought

EpiCept requests FDA priority review of Ceplene NDA for AML

Endometriosis can affect women's work productivity

BioAlliance Pharma presents abstracts on Loramyc, clonidine Lauriad at MASCC/ISOO 2010 symposium

Psychiatry and Pediatrics seeks volunteer families to participate in vitamin D study

Forest Laboratories, Gedeon Richter report positive results from radiprodil Phase II study for DPNP pain

FDA's acceptance for filing of DM-1796 NDA triggers $10M milestone payment to Depomed

UB study: Vietnam veterans exposed to Agent Orange are more likely to develop Graves' disease

New brain-to-computer chip technology revolutionizes neurological therapy

Leveraging the Radian ASAP in standard casework

A journey through science, software, and innovation: Insights from the Bruker software team

CellVoyant's AI-Powered Vision for the Future of Cell Therapy

Latest News